ASX-Dividend-Report-Banner

Innovating the Future: ISoOR 2024 Annual Meeting Achieves Remarkable Success

March 12, 2024 02:57 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Innovating the Future: ISoOR 2024 Annual Meeting Achieves Remarkable Success
Image source: Kalkine Media

SINGAPORE, March 12, 2024 /PRNewswire/ -- From March 7 to 8, 2024, the International Society of Organoid Research (ISoOR) convened its 2024 annual meeting, after the successful conference in Singapore last year. This year, the conference was held in the vibrant city of Shanghai, China, reflecting the rapid expansion of organoid industry within the country. The pivotal event was hosted by ISoOR in collaboration with Bioon and two more institutes.

Group photo of speakers
Group photo of speakers

Professor Peter E. Lobie, the chairman of ISoOR, inaugurated the conference with a warm welcome to experts, scholars, and guests around the world.

As keynote speaker invited by ISoOR, Prof. Hans Clevers, pioneer of organoid field, member of the National Academy of Sciences (USA) and head of Roche Pharma Research and Early Development, delighted the audience with a talk about Organoids to Model Human Disease, followed by more than sixty scientific experts from around the world, to exchange insights in various sessions.

Moreover, Dr. Maldonado ISoOR secretary for China region spotlighted several of ISoOR's key initiatives from the previous year, such as 2023 annual meeting in Singapore, an exciting symposium for debating the latest landmarks in organoid research, and the start-point for initiation of the ISoOR Standards for Organoid Biobanks.

Prof. Peter E. Lobie (left), Prof. Hans Clevers (middle), Dr. Maldonado (right)
Prof. Peter E. Lobie (left), Prof. Hans Clevers (middle), Dr. Maldonado (right)

The ISoOR booth at the conference provided attendees access to ISoOR official publication, the Journal of Organoid and Bioscience,(JOBs). This open-access, peer-reviewed platform encompasses a wide array of topics, including, but not limited to the Establishment of Organoid Models, Organoids in Precision Medicine, Drug Development, Regenerative Medicine, Organoid Biobanks, Policy Analysis, Current Trends in Organoid Research and Applications, and the Organoid Industry Landscape.  Additionally, the latest issue of JOBs featured a white paper offering an in-depth review of organoid and organ-on-a-chip technologies, exemplifying ISoOR's commitment to empowering the organoid community, providing researchers, industry professionals, and investors with essential knowledge for navigating the field.

ISoOR2024
ISoOR2024

The pivotal conference, which surpassed a thousand attendants, drew to a triumphant close on March 8th with organoid technology revealing vast potential in areas like disease modeling, drug development, and precision medicine, the prospects for future market growth are bright indeed. As ISoOR welcomes more members, it is poised to undertake even greater efforts to foster the advancement of organoid research.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.